| n | % |  | n | % |
---|---|---|---|---|---|
Age | Â | Â | Follow-up | Â | Â |
 median | 58 yrs |  median | 55 mo | ||
 min | 35 yrs |  min | 5 mo | ||
 max | 85 yrs |  max | 150 mo | ||
Gender |  |  | RT break > 3d |  |  |
 male | 63 | 84 |  yes | 3 | 4 |
 female | 12 | 16 |  no | 72 | 96 |
Localisation | Â | Â | SIB | Â | Â |
 oral cavity | 18 | 24 |  yes | 63 | 84 |
 oropharynx | 57 | 76 |  no | 12 | 16 |
pT stage | Â | Â | Number of beams | Â | Â |
 pT1 | 23 | 31 |  median | 9 | |
 pT2 | 36 | 48 |  min | 5 | |
 pT3 | 9 | 12 |  max | 10 | |
 pT4a | 7 | 9 |  |  |  |
 |  |  | TD nodal |  |  |
pN stage |  |  |  median | 54 Gy | |
 pN0 | 12 | 16 |  min | 50 Gy | |
 pN1 | 12 | 16 |  max | 60 Gy | |
 pN2a | 5 | 7 |  |  |  |
 pN2b | 39 | 52 | TD Boost |  |  |
 pN2c | 7 | 9 |  median | 66 Gy | |
 |  |  |  min | 60 Gy | |
clinical stage (UICC6) |  |  |  max | 70.4 Gy | |
 stage 1 | 3 | 4 |  |  |  |
 stage 2 | 7 | 9 | SD nodes |  |  |
 stage 3 | 13 | 17 |  median | 1.8 Gy | |
 stage 4a | 52 | 69 |  min | 1.8 Gy | |
 |  |  |  max | 2 Gy | |
Grading | Â | Â | Â | Â | Â |
 G1 | 2 | 3 | SD Boost |  |  |
 G2 | 43 | 57 |  median | 2.2 Gy | |
 G3 | 30 | 40 |  min | 2 Gy | |
 |  |  |  max | 2.33 Gy | |
ECE | Â | Â | Â | Â | Â |
 yes | 22 | 29 | Chemotherapy |  |  |
 no | 53 | 71 |  yes | 53 | 71 |
 |  |  |  no | 22 | 29 |
Perineural invasion | Â | Â | Â | Â | Â |
 Pn0 | 70 | 93 | CHT scheme/compl. |  |  |
 Pn1 | 5 | 7 |  Cis weekly | 47 | 89a |
 |  |  |  Carbo/5-FU | 5 | 9a |
Number of pos. nodes |  |  |  Cetuximab | 1 | 1a |
 n ≤ 2 | 44 | 59 |  >80 % of scheduled | 41 | 77a |
 n > 2 | 31 | 41 |  <80 % of scheduled | 12 | 23a |
Resection margin | Â | Â | Neck dissection | Â | Â |
 R0 | 48 | 64 |  ipsilateral | 34 | 45 |
 R1 | 27 | 36 |  bilateral | 41 | 55 |